Participants will receive study product intramuscularly (IM) in the limbs as specified by the group assignment by PharmaJet needle-free device. In Part A, 90 participants will be randomized to vaccine at a 1:1:1 ratio to receive a 4 mg or 8 mg dose of vaccine split between 2 or 4 injections. In Part B, 2400 participants will be randomized to vaccine or placebo in a 1:1 ratio to receive a 4 mg dose of vaccine or 1 mL of placebo split between 2 injections.